Search

Jennifer Lorraine Gansert

from Simi Valley, CA
Age ~56

Jennifer Gansert Phones & Addresses

  • 337 Longbranch Rd, Simi Valley, CA 93065 (805) 433-3949
  • Los Angeles, CA
  • Marina del Rey, CA
  • Port Jefferson Station, NY
  • Chicago, IL
  • Lake Grove, NY
  • East Setauket, NY
  • Ventura, CA
  • Stamford, CT
  • 337 Longbranch Rd, Simi Valley, CA 93065

Work

Position: Clerical/White Collar

Education

School / High School: State University of New York / Health Science Center At Stony Brook 1995

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Hematology, 2003

Specialities

Hematology • Medical Oncology • Oncology

Professional Records

Medicine Doctors

Jennifer Gansert Photo 1

Dr. Jennifer L Gansert, Los Angeles CA - MD (Doctor of Medicine)

View page
Specialties:
Hematology
Medical Oncology
Oncology
Address:
200 Medical Plz Suite 214, Los Angeles, CA 90095
(310) 825-0631 (Phone)
Certifications:
Hematology, 2003
Internal Medicine, 1998
Medical Oncology, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
State University of New York / Health Science Center At Stony Brook
Graduated: 1995
Medical School
University Of California-Los Angeles
Graduated: 1995
Jennifer Gansert Photo 2

Jennifer Lorraine Gansert

View page
Specialties:
Internal Medicine
Hematology & Oncology
Hematology
Medical Oncology
Education:
Stony Brook University (1995)
Jennifer Gansert Photo 3

Jennifer Lorraine Gansert, Thousand Oaks CA

View page
Specialties:
Hematologist
Address:
1 Amgen Center Dr, Thousand Oaks, CA 91320
Education:
State University of New York, School of Medicine (Stony Brook) - Doctor of Medicine
Ronald Reagan UCLA Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
Ronald Reagan UCLA Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jennifer Lorraine Gansert
Jennifer Gansert MD
Internist
200 Medical Plz Driveway, Los Angeles, CA 90024
(310) 825-0631

Publications

Us Patents

Combination Therapy

View page
US Patent:
20140023661, Jan 23, 2014
Filed:
Mar 13, 2013
Appl. No.:
13/799076
Inventors:
Xizhong Huang - Southborough MA, US
Malte Dong Eun Peters - Basel, CH
Karl Maria Schumacher - Darmstadt, DE
Zhu Alexander Cao - Acton MA, US
Jennifer Lorraine Gansert - Simi Valley CA, US
David Dong Eun Chang - Calabasas CA, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
Novartis Pharma AG - Basel
International Classification:
A61K 31/4439
A61K 39/395
US Classification:
4241721
Abstract:
The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.

Combination Therapy

View page
US Patent:
20130273061, Oct 17, 2013
Filed:
Mar 13, 2013
Appl. No.:
13/799706
Inventors:
Xizhong Huang - Southborough MA, US
Malte Peters - Basel, CH
Jennifer Lorraine Gansert - Simi Valley CA, US
David Dong Eun Chang - Calabasas CA, US
Pedro Beltran - Thousand Oaks CA, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
Novartis Pharma AG - Basel
International Classification:
A61K 39/395
A61K 31/4184
US Classification:
4241431, 4241721
Abstract:
The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

Use Of Oncolytic Viruses In The Neoadjuvant Therapy Of Cancer

View page
US Patent:
20220211784, Jul 7, 2022
Filed:
Mar 26, 2020
Appl. No.:
17/599028
Inventors:
- Thousand Oaks CA, US
Jennifer Lorraine GANSERT - Simi Valley CA, US
International Classification:
A61K 35/763
A61P 35/00
C07K 16/28
C12N 15/86
Abstract:
The invention relates to the use of an oncolytic virus in a neoadjuvant treatment regimen for the treatment of cancer.
Jennifer Lorraine Gansert from Simi Valley, CA, age ~56 Get Report